Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Status:
Completed
Trial end date:
2017-09-30
Target enrollment:
Participant gender:
Summary
This is a clinical trial with a crossover design to determine patients' preference for
capecitabine in combination with bevacizumab or everolimus in combination with exemestane for
advanced breast cancer patients and to evaluate, if any combination is associated with a
better quality of life.
To identify patients' preference for either therapy in this trial, patients without disease
progression or other reasons for early discontinuation will be asked for their treatment
preference and their treatment satisfaction. To correlate patients' preference with other
patient reported outcomes (PROs), quality of life (QoL) will be assessed at baseline and
throughout the study, using dedicated questionnaires.
With similarly active treatment options, it is of utmost importance to identify the treatment
that has the least negative impact on the patients' quality of life.